BIOTRON LIMITED (ASX:BIT) Broker Meet Biotech August 2018 Dr Michelle Miller Managing Director +61 412 313329 mmiller@biotron.com.au www.biotron.com.au
Forward Looking Statements This presenta8on may contain forward-looking statements with respect to the financial condi8on, results and business achievements/performance of Biotron Limited (ACN 086 399 144) and certain of the plans and objec8ves of its management. These statements are statements that are not historical facts. Words such as should, expects, an8cipates, es8mates, believes or similar expressions, as they relate to Biotron Limited, are intended to iden8fy forward-looking statements. By their nature, forward-looking statements involve risk and uncertainty because they reflect Biotron s current expecta8ons and assump8ons as to future events and circumstances that may not prove accurate. There is no guarantee that the expected events, trends or results will actually occur. Any changes in such assump8ons or expecta8ons could cause actual results to differ materially from current expecta8ons.
Biotron Snapshot Clinical stage anpviral drug development company with a promising pipeline of novel drug candidates targepng serious virus infecpons Lead candidate BIT225 is a novel, first-in-class, oral small molecule drug in development for treatment of HIV-1 and HepaPPs C virus (HCV) Posi8ve data in trials to date HIV-1 Phase 2 trial complete; data an8cipated end 3Q18 Provides clinical validapon of Biotron s approach to treapng serious virus infecpons Robust pipeline of first-in-class an8viral programs Headquartered in Sydney, Australia Experienced Board and management team with pharma, financial and VC backgrounds
Biotron AnPviral Focused Pipeline PROGRAM MECHANISM OF ACTION INDICATION PRECLINICAL PHASE 1/2a PHASE 2 MARKET OPPORTUNITY BIT225 Targets HIV-1 Vpu viroporin protein Targets HCV p7 viroporin protein HIV-1 Hepatitis C virus Results expected end 3Q18 Ph 2 complete; seeking partnerships in China - ~$20 bn p.a. - >36 m living with HIV-1 ww - 1.1 m in USA - ~$20 bn p.a. - Es8mated 30 50 m infected in China BIT314 Targets HCV p7 viroporin protein (next generapon) Hepatitis C virus Dengue Targets Dengue M viroporin protein Dengue - 2.5 bn live in at risk areas - ~100 m infec8ons p.a. - No drug treatment HBV, Respiratory & others Target specific virus virporin proteins HBV, Respiratory & others - Growing billion dollar markets
Biotron New Approach to AnP-Viral Drug Development Focused on the design and development of a new class of an8viral drugs targe8ng viralencoded viroporin proteins Viroporins are present in wide range of viruses: Influenza (M2), HIV-1 (Vpu), HCV (p7), Dengue and West Nile (M protein), SARS (E protein) and others Broad planorm: Rapid, proprietary primary bacterial cell-based screening assays for target proteins Focused library of compounds that target these viral proteins Pipeline of internally-generated, first-in-class small molecule viroporin inhibitors for key markets
HIV-1 EradicaPon HIV-1 remains hidden in reservoirs, leading to chronic, life-long infecpon Invisible to body s immune defenses Not sensi8ve to current an8-hiv-1 drugs New mode of ac8ons drugs are needed to eradicate or cure HIV-1 infec8on Why is HIV-1 eradicapon necessary? Long-term health implica8ons e.g. HAND, immune ac8va8on, drug-drug interac8ons Compliance/drug holidays can lead to viral rebound Cost of treatment ~ $20 billion p.a. world wide Major burden on healthcare systems
BIT225 Targets HIV-1 in Reservoir Cells BIT225 aoacks forma8on of new virus in macrophage reservoirs Phase 1b/2a trial (004) demonstrated that BIT225 can reduce HIV-1 levels in macrophage cells in vivo, paralleling in vitro studies (Wilkinson et al, J An8microb Chemother. 2015) Poten8al to add BIT225 to current treatment to clear this source of virus and improve health A (A) Untreated Controls B (B) BIT225 treated cells
BIT225-009 Phase 2 HIV-1 Trial Subjects 36 HIV-posiJve, treatment-naïve subjects commencing standard anjretroviral treatment (ART) Protocol - Double-blind, placebo-controlled, randomised, mulj-centre study - 12 weeks, once daily, oral treatment with BIT225 or placebo in combinajon with ART Primary Objec3ve Secondary Objec3ve STATUS To determine whether the addijon of BIT225 impacts on reducjon of virus levels over and above ART To determine whether BIT225 has any impact on the immune system, which may indicate addijonal benefits of the drug in pajents Clinical component complete; detailed laboratory analyses of pajent samples in progress; data expected 3Q18
Investment ProposiPon BIT drugs target high growth, mulp-billion dollar markets with defined treatment gaps HIV-1 Program - Value inflec8on points around HIV-1 program data expected in late 3Q18 HCV Program - BIT225 par8cularly well suited to Asia, with high numbers of HCV-infected pa8ents including a high propor8on of HCV/HBV co-infected pa8ents Early stage commercial collabora8on opportuni8es for pre-clinical targets, such as: Hepa88s B Respiratory viruses Seeking partners for individual targets or en8re planorm
Financial InformaPon Key Financial Metrics Ticker Code ASX: BIT Share Price (15 Aug 18) A $0.017 Market cap A $9 million 12 Month Trading Range A $0.015 - $0.042 Shares Outstanding 502 million Cash Posi8on (June 18) A $1.54 million 12 Month Share Price Performance Ticker Code ASX: BIT Share Price (15 Sept 2014) A $0.115 Market cap A $26.3 million 12 Month Trading Range A $0.075 0.315 Michael Hoy Board Non-execu8ve Chairman Shares Outstanding Cash Posi8on (06/14) 228 million A $1.76mn Michelle Miller Managing Director Susan Pond Non-execu8ve Director Rob Thomas Non-execu8ve Director